Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 5, 2013, Pages 848-853

  Freedland, Stephen J ^a,b   Gerber, Leah ^a,b   Reid, Julia ^c   Welbourn, William ^c   Tikishvili, Eliso ^c   Park, Jimmy ^c   Younus, Adib ^c   Gutin, Alexander ^c   Sangale, Zaina ^c   Lanchbury, Jerry S ^c   Salama, Joseph K ^a,b   Stone, Steven ^c  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Utah   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CELL-CYCLE PROGRESSION; EXTERNAL BEAM RADIATION THERAPY; LIKELIHOOD RATIO TESTS; METHODS AND MATERIALS; MULTIVARIABLE ANALYSIS; PROPORTIONAL HAZARDS; PROSTATE SPECIFIC ANTIGEN;

GENE EXPRESSION; GENE THERAPY; RADIOTHERAPY;

DISEASES;

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL CYCLE PROGRESSION SCORE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GENE EXPRESSION; GLEASON SCORE; HAZARD RATIO; HUMAN; HUMAN TISSUE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR GROWTH;

AGED; CELL CYCLE; GENES, CDC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84880042774     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.04.043     Document Type: Article

References (10)

1. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
2. M. Roach 3rd, F. Waldman, and A. Pollack Predictive models in external beam radiotherapy for clinically localized prostate cancer Cancer 115 2009 3112 3120
3. M.D. Hurwitz, S. Halabi, and L. Archer Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809 Cancer 117 2011 5579 5588
4. J. Cuzick, G.P. Swanson, and G. Fisher Prognostic value of an rna expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study Lancet Oncol 12 2011 245 255
5. J. Cuzick, D.M. Berney, and G. Fisher Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer 106 2012 1095 1099
6. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
7. M.J. Pencina, R.B. D'Agostino Sr., and R.B. D'Agostino Jr. Evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond Stat Med 27 2008 157 172 discussion 207-212 (Pubitemid 351193639)
8. A.S. Parker, M.G. Heckman, and K.J. Wu Evaluation of ki-67 staining levels as an independent biomarker of biochemical recurrence after salvage radiation therapy for prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1364 1370
9. J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the trog 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
10. M.R. Cooperberg, J.P. Simko, and J.E. Cowan Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort J Clin Oncol 31 2013 1428 1434